Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Decreases By 5.8%

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,780,000 shares, a drop of 5.8% from the July 31st total of 1,890,000 shares. Based on an average daily volume of 396,400 shares, the days-to-cover ratio is presently 4.5 days. Currently, 2.1% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new position in shares of Compass Therapeutics during the second quarter valued at approximately $41,000. Renaissance Technologies LLC boosted its holdings in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after buying an additional 70,200 shares in the last quarter. Ground Swell Capital LLC bought a new stake in Compass Therapeutics during the second quarter worth approximately $124,000. Rhumbline Advisers boosted its holdings in Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after buying an additional 12,315 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in Compass Therapeutics during the second quarter worth approximately $68,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CMPX. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, August 12th.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX traded up $0.04 during mid-day trading on Tuesday, reaching $1.62. 740,432 shares of the company traded hands, compared to its average volume of 419,938. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.43. The firm has a market cap of $222.89 million, a PE ratio of -4.83 and a beta of 0.79. The stock has a fifty day simple moving average of $1.07 and a 200-day simple moving average of $1.44.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $0.85 million for the quarter. As a group, analysts predict that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.